Fennec Pharmaceuticals Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting

• Most Recent News (April 21, 2026): Fennec Pharmaceuticals announced that four scientific abstracts evaluating PEDMARK® have been accepted for presentation at the 2026 ASCO Annual Meeting.
• Scope of Data: The presentations cover pediatric, adolescent, and adult populations including Germ Cell Tumor (GCT) and Head and Neck Cancer.
• Timing: Full abstracts available May 21, 2026; meetings scheduled May 29 – June 2, 2026.
• Historical Context: This follows a series of clinical updates including:
  • March 2026: Q4 and FY 2025 financial results showing record sales ($44.6M) but net loss ($10.1M).
  • March 2026: Settlement agreement with Cipla delaying generic entry until September 1, 2033.
  • February 2026: Real-world data presented supporting use in adult Head & Neck cancer patients (≥6 hours post-cisplatin).
  • December 2025: Positive topline results from Japan STS-J01 trial.
• Financing History: November 2025 saw a $42M public offering and debt redemption, eliminating all convertible notes.

• Current News Impact (Routine): The ASCO abstract acceptance is an expected milestone given the active clinical pipeline announced in Q3/Q4 2025. It does not introduce new efficacy data or regulatory approvals but confirms ongoing scientific interest.
• Market Reaction Context: Despite strong FY sales growth (+50%), the stock dropped from ~$10.70 to $8.26 immediately following the March 24 earnings release, indicating investor concern over profitability margins and cash burn despite revenue beats.
• Patent Settlement (Material Positive): The Cipla settlement is a significant material positive event securing exclusivity until 2033, protecting the core revenue stream from generic competition for at least seven years.
• Financial Health: Debt elimination ($21.7M redeemed) and cash position ($36.8M) improve solvency risk, but high G&A expenses ($28.8M FY) suggest operational inefficiency relative to sales growth.
• Overall Assessment: The news is incremental validation of the clinical strategy rather than a fundamental shift in valuation drivers. It supports the narrative established by the patent settlement and Japan trial results but lacks immediate catalyst for price appreciation beyond current levels.

• Company: Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX).
• Flagship Product: PEDMARK® (sodium thiosulfate injection).
• Indication: Prevention of cisplatin-induced ototoxicity (hearing loss) in pediatric patients with localized non-metastatic solid tumors.
• Approval Status: FDA approved September 2022; EMA and UK approvals obtained June/October 2023 under PEDMARQSI®.
• NCCN Endorsement: NCCN 2A recommendation for Adolescent/Young Adult (AYA) use.
• Commercial Strategy: Expanding into adult oncology markets (Head & Neck, Testicular GCT) via real-world evidence and investigator-sponsored studies to broaden the addressable patient population (~500k U.S. patients annually).